Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

被引:419
作者
Halama, Niels [1 ,2 ,3 ]
Zoernig, Inka [1 ]
Berthel, Anna [1 ,2 ]
Kahlert, Christoph [4 ]
Klupp, Fee [4 ]
Suarez-Carmona, Meggy [1 ]
Suetterlin, Thomas [1 ,2 ]
Brand, Karsten [5 ]
Krauss, Juergen [1 ]
Lasitschka, Felix [5 ]
Lerchl, Tina [1 ,2 ]
Luckner-Minden, Claudia [1 ]
Ulrich, Alexis [4 ]
Koch, Moritz [6 ]
Weitz, Juergen [6 ]
Schneider, Martin [4 ]
Buechler, Markus W. [4 ]
Zitvogel, Laurence [7 ]
Herrmann, Thomas [8 ]
Benner, Axel [9 ]
Kunz, Christina [9 ]
Luecke, Stephan [9 ]
Springfeld, Christoph [1 ]
Grabe, Niels [1 ,2 ]
Falk, Christine S. [10 ]
Jaeger, Dirk [1 ,2 ]
机构
[1] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, BIOQUANT, Natl Ctr Tumor Dis, Tissue Imaging & Anal Ctr, D-69120 Heidelberg, Germany
[3] Univ Heidelberg Hosp, Inst Immunol, D-69120 Heidelberg, Germany
[4] Univ Heidelberg Hosp, Dept Surg, D-69120 Heidelberg, Germany
[5] Univ Heidelberg Hosp, Inst Pathol, D-69120 Heidelberg, Germany
[6] Univ Hosp Dresden, Dept Surg, D-01307 Dresden, Germany
[7] IGR, INSERM U1015, F-94805 Villejuif, France
[8] Klinikum Idar Oberstein, Dept Internal Med 1, D-55743 Idar Oberstein, Germany
[9] German Canc Res Ctr, Div Biostat, D-69120 Heidelberg, Germany
[10] Hannover Med Sch, Integrated Res & Treatment Ctr Transplantat, Inst Transplant Immunol, D-30625 Hannover, Germany
关键词
MIGRATION INHIBITORY FACTOR; CHEMOKINE RECEPTOR CCR5; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; IMMUNOTHERAPY; INFLAMMATION; CHEMOTHERAPY; PROGRESSION; ANTAGONIST; EXPRESSION;
D O I
10.1016/j.ccell.2016.03.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune response influences the clinical course of colorectal cancer (CRC). Analyzing the invasive margin of human CRC liver metastases, we identified a mechanism of immune cell exploitation by tumor cells. While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5. CCR5 blockade in patientderived functional in vitro organotypic culture models showed a macrophage repolarization with anti-tumoral effects. These anti-tumoral effects were then confirmed in a phase I trial with a CCR5 antagonist in patients with liver metastases of advanced refractory CRC. Mitigation of tumor-promoting inflammation within the tumor tissue and objective tumor responses in CRC were observed.
引用
收藏
页码:587 / 601
页数:15
相关论文
共 52 条
[1]   Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers [J].
Abel, Samantha ;
van der Ryst, Elna ;
Rosario, Maria C. ;
Ridgway, Caroline E. ;
Medhurst, Christine G. ;
Taylor-Worth, Richard J. ;
Muirhead, Gary J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 :5-18
[2]   A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis [J].
Acharyya, Swarnali ;
Oskarsson, Thordur ;
Vanharanta, Sakari ;
Malladi, Srinivas ;
Kim, Juliet ;
Morris, Patrick G. ;
Manova-Todorova, Katia ;
Leversha, Margaret ;
Hogg, Nancy ;
Seshan, Venkatraman E. ;
Norton, Larry ;
Brogi, Edi ;
Massague, Joan .
CELL, 2012, 150 (01) :165-178
[3]   B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas [J].
Affara, Nesrine I. ;
Ruffell, Brian ;
Medler, Terry R. ;
Gunderson, Andrew J. ;
Johansson, Magnus ;
Bornstein, Sophia ;
Bergsland, Emily ;
Steinhoff, Martin ;
Li, Yijin ;
Gong, Qian ;
Ma, Yan ;
Wiesen, Jane F. ;
Wong, Melissa H. ;
Kulesz-Martin, Molly ;
Irving, Bryan ;
Coussens, Lisa M. .
CANCER CELL, 2014, 25 (06) :809-821
[4]   The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation [J].
Albini, Adriana ;
Benelli, Roberto .
NATURE PROTOCOLS, 2007, 2 (03) :504-511
[5]   Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer [J].
Arkenau, Hendrik-Tobias ;
Brunetto, Andre T. ;
Barriuso, Jorge ;
Olmos, David ;
Eaton, David ;
de Bono, Johann ;
Judson, Ian ;
Kaye, Stan .
ONCOLOGY, 2009, 76 (03) :151-156
[6]   Inflammation-Induced Hepatocellular Carcinoma Is Dependent on CCR5 in Mice [J].
Barashi, Neta ;
Weiss, Ido D. ;
Wald, Ori ;
Wald, Hanna ;
Beider, Katia ;
Abraham, Michal ;
Klein, Shiri ;
Goldenberg, Daniel ;
Axelrod, Jonathan ;
Pikarsky, Eli ;
Abramovitch, Rinat ;
Zeira, Evelyne ;
Galun, Eithan ;
Peled, Amnon .
HEPATOLOGY, 2013, 58 (03) :1021-1030
[7]   Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? [J].
Coussens, Lisa M. ;
Zitvogel, Laurence ;
Palucka, A. Karolina .
SCIENCE, 2013, 339 (6117) :286-291
[8]   Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression [J].
DeNardo, David G. ;
Coussens, Lisa M. .
BREAST CANCER RESEARCH, 2007, 9 (04)
[9]   Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy [J].
DeNardo, David G. ;
Brennan, Donal J. ;
Rexhepaj, Elton ;
Ruffell, Brian ;
Shiao, Stephen L. ;
Madden, Stephen F. ;
Gallagher, William M. ;
Wadhwani, Nikhil ;
Keil, Scott D. ;
Junaid, Sharfaa A. ;
Rugo, Hope S. ;
Hwang, E. Shelley ;
Jirstroem, Karin ;
West, Brian L. ;
Coussens, Lisa M. .
CANCER DISCOVERY, 2011, 1 (01) :54-67
[10]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732